Technology News and Research

RSS

Study: 82% of Georgia hospitals do not offer palliative care services

Hospitals across the nation are increasingly implementing palliative care programs to help patients manage the physical and emotional burdens of serious illnesses, but a new University of Georgia study finds that 82 percent of the state's hospitals do not offer palliative care services.

12 Jul 2011

BioAlliance receives European patent for Livatag to treat primary liver cancer

BioAlliance Pharma SA, a company dedicated to specialty and orphan oncology products, today announces the grant of a European patent protecting its Transdrug nanotechnology.

12 Jul 2011

New ‘world-first’ Malaria vaccine in the pipeline

Australian researchers have potentially created a ‘world-first’ malaria vaccine that could save millions of lives. According to Professor Michael Good, of Griffith University in Queensland, his team have found a way to completely protect mice against multiple strains of malaria. The team hopes to begin human trials over the next year to see if it produces a similar response.

12 Jul 2011

Viewpoints: N.Y. health exchange stalemate; Dick Cheney's heart; vaccine debate refuses to die

Just in case you hadn't noticed, no one has elected Grover Norquist to anything. Still, he looms as a major obstacle to Congress reaching a deficit-reduction agreement needed to raise the federal debt ceiling. … what's revealing about Norquist's passionate advocacy against taxes is that it virtually ignores the main causes of bigger government: Social Security and Medicare.

12 Jul 2011

Toumaz announces JV for newly approved ‘digital plaster’

Toumaz Limited (AIM: TMZ,) has established a new joint venture with Dr. Patrick Soon-Shiong’s company California Capital Equity LLC (‘CCE’), to expand the commercialisation and distribution of the Sensium™ Digital Plaster. The joint venture, which is named “Toumaz US LLC”, will be headquartered in San Diego, California, and will sell and distribute the Sensium™ Digital Plaster in North America and Worldwide.

11 Jul 2011

Novis opens fifth office location in San Luis Obispo

Novis Pharmaceuticals, a leading distributor of critical care products, has officially opened their fifth office location in San Luis Obispo, California. With more than 30 years of industry experience, Novis' aggressive plan to expand their national presence continues to move forward with news of this location opening. Placed strategically between San Francisco and Los Angeles, Novis believes this will help capture parts of the regional market.

11 Jul 2011

Parallels, Microsoft partner to deliver complete cloud automation solution for health community

At the Microsoft World Wide Partner conference, Parallels today announced a two-year strategic relationship with Microsoft to deliver a complete cloud automation solution focused on meeting the needs of the health industry around the world.

11 Jul 2011

Evolution Benefits and Lighthouse1 merge to create Evolution1

Evolution Benefits and Lighthouse1 announced today that they have completed merging their companies to create Evolution1. Evolution1 offers the nation's most comprehensive electronic payment, on-premise and cloud computing solutions for the administration of flexible spending accounts (FSAs), health savings accounts (HSAs), health reimbursement accounts (HRAs), VEBAs, wellness and transit plans.

11 Jul 2011

RyMed's InVision-Plus Intraluminal Protection System effective against catheter-related bloodstream infections

Denise Macklin, BSN, RNC, representing the research team of Dr. Cynthia C. Chernecky Ph.D., RN, AOCN, FAAN, Dr. Jennifer Waller, Ph.D., both from Georgia Health Sciences University; and Dr. William Jarvis M.D., Jason & Jarvis Associates, exhibited a poster at the recent APIC 2011 (Association for Professionals in Infection Control and Epidemiology) conference in Baltimore, titled "Clinical Comparisons of Split Septum, Positive and Negative Mechanical Valve Intravenous Connectors to an Intraluminal Protection Connector on Infection Rates."

11 Jul 2011

Research validates SpinalCyte's core technology to regrow the spinal disc

SpinalCyte, LLC, a spinal technology company focused on autologous regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the publication of its research completed with Rice University, titled, "Chondrogenic Differentiation of Neonatal Human Dermal Fibroblasts Encapsulated in Alginate Beads with Hydrostatic Compression Under Hypoxic Conditions in the Presence of Bone Morphogenetic Protein-2".

11 Jul 2011

FDA clears TearScience's LipiFlow Thermal Pulsation System for evaporative dry eye

TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.

11 Jul 2011

FDA-approved Zuplenz oral soluble film now available for licensing to new commercial partners

MonoSol Rx, a specialty pharmaceutical company and the developers of the PharmFilm technology platform, in collaboration with APR Applied Pharma Research s.a. of Switzerland, announced today that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is available for licensing to new commercial partners.

11 Jul 2011

'Vanishing' girl population in India

India must urgently tackle its "vanishing" girl population as the nation awaits the birth of the world's seven billionth baby, says child rights organisation Plan International.

11 Jul 2011

iBio successfully produces human plasma proteins using proprietary technology

iBio, Inc. today announced successful production of human plasma proteins using its proprietary iBioLaunch technology. Human alpha 1-antitrypsin and human C1 esterase inhibitor were successfully produced at high yield in green plants via the Company's proprietary iBioLaunch technology. Both of these proteins are important therapeutic products, but until now they have been made from human blood.

11 Jul 2011

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-PCS, an RNAi therapeutic for the treatment of severe hypercholesterolemia.

11 Jul 2011

Ion Torrent ships three next-generation sequencers

Ion Torrent, a unit of Life Technologies Corporation, today announced that it is shipping its new 100 Mb Ion 316 chip, which has tenfold more throughput than the original Ion 314 chip, and that its 1 Gb Ion 318 chip will be available in the fourth quarter.

11 Jul 2011

BGI, Covaris partner to provide next generation sequencing technology

BGI and Covaris, Inc. today announced a deal that will integrate Covaris' Adaptive Focused Acoustics AFA DNA shearing technology across several BGI laboratories in China.

11 Jul 2011

Endosense completes first patient case utilizing new prototype software

Endosense, a Swiss medical technology company, has announced completion of the first patient case utilizing prototype software that integrates the contact-force data provided by Endosense's TactiCath force-sensing ablation catheter with Siemens Healthcare's electrophysiology solutions.

11 Jul 2011

Illumina, Sequenom sign three-year supply agreement

Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, today announced it has signed a three-year supply agreement with Illumina, Inc., a leading developer and manufacturer of life sciences tools for the large-scale analysis of genetic variation and function.

From Illumina, Inc. 11 Jul 2011

USPTO issues notice of allowance to PROLOR Biotech's CTP platform

PROLOR Biotech, Inc., today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering the company's CTP platform, which has the potential to extend the duration of activity of virtually all therapeutic proteins.

11 Jul 2011